Systemic Treatments for Lung Cancer Patients Receiving Hemodialysis

Leung, Tzewah V; Hughes, Mitchell E.; Cambareri, Christine; Rubin, Daniel J.; Eaby-Sandy, Beth

doi:10.6004/jadpro.2018.9.6.4

Cited by 2 publications

(2 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is believed that the reduction in the initial dose of topotecan by 50–75% is recommended for ESRD patients on non-HD days or after the HD session. 9 …”

Section: General Considerationsmentioning

confidence: 99%

“…The plasma concentrations of etoposide were comparable to those of patients with normal renal function. 9 A 30-year-old patient on HD with poor risk metastatic non-seminomatous germ cell tumor received five cycles of full dose of cisplatin and 60% dose of etoposide on days 1–5, every 21 days and strategically timed with HD. Some studies have indicated that standard-dose chemotherapy with etoposide is feasible and effective in patients undergoing hemodialysis.…”

Section: General Considerationsmentioning

confidence: 99%

See 1 more Smart Citation

Systemic Treatment for Gynecological Cancer Patients Undergoing Hemodialysis

Zhang¹,

Liu²,

Wen³

2023

OTT

View full text Add to dashboard Cite

Gynecological cancer poses a serious threat to women’s health. Chemotherapy-based systemic therapy plays a crucial role in the treatment of gynecological cancers. Many systemic therapeutic drugs are metabolized in the kidneys. Therefore, normal renal function is a prerequisite for gynecological tumor patients to complete the full course of systematic treatment and provide a guarantee for achieving an ideal prognosis. Chronic kidney disease often places restrictions on systematic treatment to different extents, such as influencing drug pharmacokinetics, increasing drug toxicity, and the risk of adverse drug reactions. Unfortunately, women undergoing renal replacement have a higher risk of developing gynecological cancers. This article summarizes the current knowledge on systemic treatment drugs for patients with gynecological cancer undergoing dialysis. We discuss the optimal choice of the systematic therapeutic protocol, administration of form and dosage, and window of chemotherapy during hemodialysis sessions to ensure both effectiveness and safety in gynecological cancer patients.

show abstract

“…It is believed that the reduction in the initial dose of topotecan by 50–75% is recommended for ESRD patients on non-HD days or after the HD session. 9 …”

Section: General Considerationsmentioning

confidence: 99%

Section: General Considerationsmentioning

confidence: 99%

Systemic Treatment for Gynecological Cancer Patients Undergoing Hemodialysis

Zhang¹,

Liu²,

Wen³

2023

OTT

View full text Add to dashboard Cite

show abstract

A Case of Advanced Squamous Cell Lung Cancer with Hemodialysis That Responded to Carboplatin and Nab-paclitaxel Combination Therapy After Progression on Pembrolizumab

Sai,

Chihara,

Takahashi

et al. 2023

JJLC

View full text Add to dashboard Cite

━━ Background. Patients with non-small cell lung cancer on hemodialysis have limited treatment options, and the prognosis is often severe because standard treatment cannot be administered. Case. A 70-year-old man with chronic kidney dysfunction was diagnosed with cT2aN1M0 stage IIB non-small cell lung cancer, and thoracoscopic left upper lobe resection was performed. One year later, recurrence due to liver metastasis was detected and pembrolizumab was administered as first-line therapy because the tumor showed a high PD-L1 expression level. Hemodialysis was introduced during treatment, and pembrolizumab treatment led to a partial response. After 11 courses of pembrolizumab, liver metastasis increased. The patient was subsequently treated with four courses of carboplatin and nab-paclitaxel as second-line therapy, which resulted in a partial response. Although blood transfusion was required for grade 3 anemia, the adverse events were manageable, end the patient was discharged from hospital. The third and fourth courses of treatment were continued as outpatient treatment. Conclusion. Combination chemotherapy with carboplatin and nab-paclitaxel after progression on pembrolizumab may be administered for patients with non-small cell lung cancer who are receiving hemodialysis, as it is efficient and tolerable.

show abstract

Systemic Treatments for Lung Cancer Patients Receiving Hemodialysis

Cited by 2 publications

References 52 publications

Systemic Treatment for Gynecological Cancer Patients Undergoing Hemodialysis

Systemic Treatment for Gynecological Cancer Patients Undergoing Hemodialysis

A Case of Advanced Squamous Cell Lung Cancer with Hemodialysis That Responded to Carboplatin and Nab-paclitaxel Combination Therapy After Progression on Pembrolizumab

Contact Info

Product

Resources

About